Discovery of P1-P2 depeptidized boronic acid based Plasmodium falciparum SUB1 inhibitor

Malaria is a relentless parasite that hides inside human red blood cells, multiplying until it bursts free to infect new cells. This escape, or egress, is a critical moment in the parasite's life cycle, and it relies on a specific molecular tool: an enzyme called SUB1. Think of SUB1 as a specialized pair of scissors that the parasite must use to cut through the membranes holding it captive. If these scissors are jammed or broken, the parasite cannot escape, cannot spread, and eventually dies. Because this enzyme is essential for the parasite's survival but looks different from human enzymes, it offers a promising target for new medicines. The challenge for scientists has been to design a drug that jams these scissors effectively without harming the human host or being too complex for the body to absorb.

For some time, researchers have known that certain chemical structures called peptidic boronic acids can act as powerful inhibitors, or stoppers, for this enzyme. These molecules work by mimicking the natural proteins the enzyme usually cuts, allowing them to bind tightly to the active site and block its function. However, these early inhibitors were built like long chains of amino acids, making them highly "peptidic." While effective in a test tube, this peptidic nature made them difficult to use as drugs; they struggled to pass through cell membranes and were often unstable in the body. The goal of the new research was to simplify these molecules, stripping away the complex chain-like parts while keeping the core mechanism that stops the enzyme.

A team of scientists, working across institutions in Latvia, the United Kingdom, and the United States, set out to redesign these inhibitors. They started by looking at the three-dimensional structure of the enzyme and the way the best existing inhibitors fit inside it. Using computer modeling, they realized that a specific section of the inhibitor, consisting of two amino acid units, was not making critical contacts with the enzyme's active site. This observation suggested that this part could be removed and replaced with a much simpler, ring-shaped structure without losing the ability to bind. They replaced the two-amino-acid segment with a core made of a benzene ring attached to a boronic acid group, creating a "depeptidized" version that was smaller and potentially more drug-like.

The researchers then synthesized a series of these new, simplified molecules and tested them against the malaria enzyme in the lab. Their first major discovery was that the position of a specific chemical group on the benzene ring mattered immensely. When they attached a carboxylic acid group to the middle of the ring, the molecule became a remarkably potent inhibitor. This specific version, which they named compound 3a, stopped the enzyme from working at extremely low concentrations, requiring only about ten nanograms per milliliter to be effective. This was a significant improvement over the simpler version without the acid group. The team determined through computer simulations that this improvement came from the acid group forming a strong electrical attraction with a specific part of the enzyme, effectively locking the inhibitor in place.

To ensure these findings could lead to real-world medicines, the team explored whether they could replace the carboxylic acid with other chemical groups that might behave similarly but have better properties. They tested various alternatives, including groups that mimic the acid's shape and charge. One particular replacement, an N-acylsulfonamide group, proved to be almost as effective as the original acid, maintaining high potency against the enzyme. However, other attempts to swap the acid for different structures, such as changing the ring itself to a furan or moving the acid group to a different spot on the ring, resulted in molecules that failed to stop the enzyme entirely. This told the researchers that the specific geometry and chemical nature of the acid group were non-negotiable for this type of inhibitor.

While the new inhibitors were excellent at stopping the enzyme in a test tube, the story became more complex when the researchers tested them on living malaria parasites growing in human red blood cells. In these cellular assays, the best inhibitors showed activity, but they were much weaker than they were in the test tube, requiring concentrations in the low micromolar range to slow the parasite's growth. The researchers suspect that this drop in performance is due to the difficulty these molecules face in crossing the multiple membranes of the host cell and the parasite itself to reach their target. The enzyme is stored in a specific compartment inside the parasite called the exoneme, and the new, smaller molecules may not be penetrating these barriers efficiently enough to reach the enzyme before the parasite escapes.

The study concludes that while the strategy of simplifying the inhibitor by removing the peptide chain was successful in creating a highly potent enzyme blocker, the journey to a usable drug is not yet complete. The team has validated that a benzene-boronic acid core can effectively target the malaria enzyme, and they have identified the precise chemical features needed to make it bind tightly. However, the gap between stopping the enzyme in a dish and stopping the parasite in a cell suggests that further modifications are needed to help the drug penetrate biological barriers. This work provides a clear roadmap for the next generation of malaria treatments, showing exactly which chemical changes improve potency and which ones need to be refined to overcome the challenges of getting a drug inside a living cell.